Dae Hwa Pharm Co (XKRX:067080) ROCE % : 51.12% (As of Mar. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Dae Hwa Pharm Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Dae Hwa Pharm Co's annualized ROCE % for the quarter that ended in Mar. 2024 was 51.12%.

Dae Hwa Pharm Co ROCE % Historical Data

The historical data trend for Dae Hwa Pharm Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dae Hwa Pharm Co ROCE % Chart

Dae Hwa Pharm Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

18.70

4.78

6.06

4.40

4.07

Dae Hwa Pharm Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															9.00	4.36	-0.99	2.61	51.12

Dae Hwa Pharm Co ROCE % Calculation

Dae Hwa Pharm Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	4217.615	/	( ( (199056.473 - 83259.7)	+	(219162.617 - 127947.714) )	/ 2 )
	=	4217.615	/	( (115796.773	+	91214.903)	/ 2 )
	=	4217.615	/	103505.838
	=	4.07 %

Dae Hwa Pharm Co's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	46128.52	/	( ( (219162.617 - 127947.714)	+	(219185.455 - 129918.282) )	/ 2 )
	=	46128.52	/	( ( 91214.903	+	89267.173 )	/ 2 )
	=	46128.52	/	90241.038
	=	51.12 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Dae Hwa Pharm Co (XKRX:067080) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Dae Hwa Pharm Co ROCE % Related Terms

Thank you for viewing the detailed overview of Dae Hwa Pharm Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Dae Hwa Pharm Co (XKRX:067080) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dae Hwa Pharm Co Ltd (XKRX:067080) » Definitions » ROCE %

Traded in Other Exchanges

N/A

Address

495 Hanu-ro, Hoengseong-eup, Hoengseong-gun, Seoul, Gangwon-do, KOR, 225-804

Website

http://www.dhpharm.co.kr

Dae Hwa Pharm Co Ltd is a specialized pharmaceutical company. It is mainly involved in manufacturing and distribution of pharmaceutical products. The company controls approximately 70% of the domestic transdermal drug delivery system market. The company offers analgesics and anti-inflammatory drugs, antihistamines, skeletal muscle relaxants, and cardiovascular drugs. Its products are exported to Asia, South America, Africa, and the Middle East.

Dae Hwa Pharm Co (XKRX:067080) Headlines

No Headlines